BIO Word Congress addresses applications of synthetic biology
The Biotechnology Industry Organization's fourth annual World Congress on Industrial Biotechnology and Bioprocessing held in Orlando, USA, has received a presentation on the use of genetic engineering to produce a yeast that can synthesize cheap artemisinin, an antimalarial drug.
In a speech titled: Redesigning Life from the Ground Up: Applications and Implications of Synthetic Biology, Jay Keasling, the University of California Berkeley Center for Synthetic Biology's director, described his work on new genes from the Artemisia annua plant, as well as other projects related to biofuels. Dr Keasling said: "renewable energy and medicines for the developing world are certainly problems that we can solve."
A revolution based on industrial biotechnology
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze